NZ621196A - Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage - Google Patents

Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Info

Publication number
NZ621196A
NZ621196A NZ621196A NZ62119609A NZ621196A NZ 621196 A NZ621196 A NZ 621196A NZ 621196 A NZ621196 A NZ 621196A NZ 62119609 A NZ62119609 A NZ 62119609A NZ 621196 A NZ621196 A NZ 621196A
Authority
NZ
New Zealand
Prior art keywords
tissue
preventing
disorders associated
treating diseases
peptide analogs
Prior art date
Application number
NZ621196A
Other languages
English (en)
Inventor
Anthony Cerami
Michael Brines
Original Assignee
Araim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araim Pharmaceuticals Inc filed Critical Araim Pharmaceuticals Inc
Publication of NZ621196A publication Critical patent/NZ621196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
NZ621196A 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage NZ621196A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6202208P 2008-01-22 2008-01-22
US6204508P 2008-01-22 2008-01-22
US6201208P 2008-01-22 2008-01-22
US13391208P 2008-07-03 2008-07-03
US20389008P 2008-12-30 2008-12-30
NZ601868A NZ601868A (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Publications (1)

Publication Number Publication Date
NZ621196A true NZ621196A (en) 2015-08-28

Family

ID=40810017

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ621196A NZ621196A (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ601868A NZ601868A (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ587105A NZ587105A (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ601868A NZ601868A (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ587105A NZ587105A (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Country Status (15)

Country Link
US (4) US8853358B2 (enExample)
EP (2) EP2933264A3 (enExample)
JP (5) JP5542064B2 (enExample)
KR (7) KR20190085187A (enExample)
CN (4) CN102066413B (enExample)
AU (1) AU2009206748B2 (enExample)
CA (1) CA2712757A1 (enExample)
ES (1) ES2539124T3 (enExample)
HK (1) HK1215713A1 (enExample)
IL (1) IL207155A (enExample)
MX (3) MX2010008050A (enExample)
NZ (3) NZ621196A (enExample)
PL (1) PL2245056T4 (enExample)
SG (3) SG188161A1 (enExample)
WO (1) WO2009094172A2 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
SI2371855T1 (sl) 2005-08-05 2015-11-30 Araim Pharmaceuticals, Inc. Peptidi, ki ščitijo tkiva, in načini njihove uporabe
NZ621196A (en) 2008-01-22 2015-08-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
ES2773017T3 (es) 2010-04-06 2020-07-09 Synedgen Inc Derivados de quitosano para el tratamiento de mucositis o ulceración
US9999702B2 (en) * 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
WO2012069474A2 (en) 2010-11-24 2012-05-31 H. Lundbeck A/S A method for reducing potential virus burden in a sample by cyanate treatment
EP2656079A2 (en) * 2010-12-20 2013-10-30 Universiteit Gent Crystal structure of flt3 ligand-receptor complex
AU2012271781C1 (en) * 2011-06-13 2017-09-21 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
FR2978964B1 (fr) * 2011-08-09 2015-02-20 Conservatoire Nat Arts Composition vaccinale anti-il-6
WO2013072901A2 (en) * 2011-11-17 2013-05-23 Btm Mazowsze Sp. Zo.O. Compositions and methods for treating glioma
US10022393B2 (en) * 2012-09-20 2018-07-17 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation, trauma or shock
WO2014121063A1 (en) * 2013-01-31 2014-08-07 The Trustees Of The University Of Pennsylvania Repair of peripheral nerve injury
WO2014144095A2 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Oklahoma Compositions comprising d-amino acid peptides and methods of production and use thereof for inhibiting autoantibodies
KR20160052537A (ko) * 2013-07-17 2016-05-12 아라임 파마슈티칼즈, 인크. 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
KR101510743B1 (ko) 2013-07-23 2015-04-10 (주)케어젠 파골 세포 분화 억제용 펩타이드 및 이의 용도
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CN108125965B (zh) * 2014-04-25 2020-04-10 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇及其类似物在高原病中的应用
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
WO2016172693A1 (en) * 2015-04-23 2016-10-27 Rowan University Novel slice cultures and methods for diagnosing neuronal degeneration diseases
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
RU2613308C1 (ru) * 2015-11-23 2017-03-15 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования предрасположенности к послеоперационному кровотечению при раке головки поджелудочной железы
AU2017248756B2 (en) 2016-04-14 2022-08-04 The Trustees Of The University Of Pennsylvania Implantable living electrodes and methods for use thereof
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3448415A4 (en) * 2016-04-29 2019-11-06 Araim Pharmaceuticals, Inc. TREATMENT-PROOFING PEPTIDES FOR THE PREVENTION AND TREATMENT OF DISEASES AND DISORDERS RELATED TO TISSUE DAMAGE
CN106075392B (zh) * 2016-07-18 2020-07-07 滨州医学院 促红细胞生成素衍生物在听力保护上的应用
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
JP7123932B2 (ja) * 2016-09-02 2022-08-23 クリストファー ジェイ． ソアレス 神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用
AU2017357374B2 (en) * 2016-11-10 2023-05-18 Asc Regenity Ltd. Cosmetic formulations for topical applications containing erythropoietin-derived molecules
KR101965814B1 (ko) * 2017-02-27 2019-08-13 재단법인 대구경북과학기술원 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용
JP6450999B2 (ja) * 2017-03-31 2019-01-16 国立大学法人群馬大学 Ｂ型ボツリヌス毒素を用いたレイノー現象の治療
EP3619324B1 (en) * 2017-05-05 2025-07-09 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN110590919B (zh) * 2017-05-24 2022-05-24 中国海洋大学 含鸟氨酸的短肽及其应用
JP7267998B2 (ja) * 2017-08-19 2023-05-02 オハイオ・ステイト・イノベーション・ファウンデーション 新規ペプチド系癌造影剤
WO2019058263A1 (en) * 2017-09-19 2019-03-28 Auckland Uniservices Limited PEPTIDES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF ADIPONECTIN
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
US10975124B2 (en) 2018-02-23 2021-04-13 The Board Of Regents Of The University Of Oklahoma Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor
KR102167641B1 (ko) 2018-08-27 2020-10-19 주식회사 사이루스 에리스로포이에틴 유래 펩티드를 함유하는 세포증식 촉진용 조성물
WO2020055768A1 (en) 2018-09-10 2020-03-19 Cold Spring Harbor Laboratory Methods for treating pancreatitis
KR20200080179A (ko) * 2018-12-26 2020-07-06 아미코젠주식회사 아세틸콜린 수용체 저해 펩타이드 및 이의 용도
CN113993523A (zh) * 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
WO2021137932A1 (en) * 2019-11-04 2021-07-08 Faraday Pharmaceuticals, Inc. Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity
US12044516B2 (en) 2020-02-06 2024-07-23 Austin Star Detonator Company Integrated detonator sensors
KR102387136B1 (ko) * 2020-04-06 2022-04-14 재단법인대구경북과학기술원 탈모의 예방 또는 치료용 펩티드 및 이의 이용
WO2021245677A1 (en) * 2020-06-05 2021-12-09 Digestix Bioscience Inc. Compositions and methods for treating dysplastic and early-stage neoplastic conditions
CN111863118B (zh) * 2020-07-20 2023-09-05 湖南莱博赛医用机器人有限公司 基于tct制片进行tct和dna倍体分析的方法
CN112557347B (zh) * 2020-11-12 2023-10-24 渤海大学 一种黏液层中乳糜粒子迁移模型的制备及检测方法
US12492223B2 (en) 2021-07-23 2025-12-09 Lateral IP Pty Ltd Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof
CN117813105A (zh) * 2021-07-23 2024-04-02 横向知识产权私人有限公司 能够结合羊毛硫氨酸合成酶c-样蛋白(lancl)的肽组合物及其用途
CN114606317B (zh) * 2022-03-22 2022-12-02 中山大学附属第一医院 一种预测胃癌淋巴结转移的菌群标志物及其应用
CN117106057B (zh) * 2022-08-19 2024-11-01 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法
GB202215797D0 (en) 2022-10-25 2022-12-07 Solasta Bio Ltd Insect neuropeptide analogues
CN116983469B (zh) * 2023-08-03 2025-11-21 东华大学 一种水凝胶支架及其制备方法和应用
US12302908B2 (en) 2023-10-23 2025-05-20 Solasta Bio Limited Insect neuropeptides 4
US12245596B1 (en) * 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 8
US12245588B1 (en) 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 2
US12279621B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 3
US12281143B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 1
US12356995B2 (en) 2023-10-23 2025-07-15 Solasta Bio Limited Insect neuropeptides 9

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (enExample) 1975-05-30 1978-03-15 Battelle Memorial Institute
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
DE3924746A1 (de) 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US6932968B1 (en) 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US6849602B1 (en) 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
US6271196B1 (en) 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US5952293A (en) 1996-03-08 1999-09-14 Receptron Receptor derived peptides involved in inhibition of receptor internalization in response to ligand binding
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
TR200103785T2 (tr) 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
AU2001252650A1 (en) 2000-04-28 2001-11-12 Effector Cell Institute Novel derivative of cell chemotactic factor
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
AU7490401A (en) * 2000-05-26 2001-12-11 Ortho Mcneil Pharm Inc Neuroprotective peptides
AU2002217984A1 (en) 2000-11-30 2002-06-11 Henry M. Jackson Foundation Erythropoietin and erythropoietin receptor expression in human cancer
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
AU2003256336A1 (en) 2002-06-28 2004-01-19 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
EA010200B1 (ru) * 2002-07-01 2008-06-30 Дзе Кеннет С. Уоррен Инститьют, Инк. Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
EP1545586A4 (en) 2002-09-09 2007-09-26 Warren Pharmaceuticals Inc LONG-ACTING ERYTHROPOIETINES THAT MAINTAIN THE PROTECTIVE ACTIVITY OF THE TISSUE OF ENDOGENEURY ERYTHROPOIETIN
JP2004305006A (ja) 2003-04-01 2004-11-04 Japan Science & Technology Agency 人工調製肺サーファクタント
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
NZ543905A (en) 2003-05-12 2008-07-31 Affymax Inc Peptides that bind to the erythropoietin receptor
WO2005021579A2 (en) 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
BRPI0409650A (pt) 2003-09-09 2006-04-25 Warren Pharmaceuticals Inc métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
AU2004277954A1 (en) 2003-09-29 2005-04-14 The Kenneth S Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20050090551A1 (en) 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
SI1718338T1 (sl) 2004-02-02 2015-09-30 Engeneic Molecular Delivery Pty Ltd. Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
EA200901236A1 (ru) * 2004-03-16 2009-12-30 Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Замещённые фенокси- и фенилтиопроизводные для лечения пролиферативных нарушений
US20050267027A1 (en) 2004-04-05 2005-12-01 Lounsbury Karen M Use of erythropoietin for treatment of cancer
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP2385061A3 (en) 2005-05-10 2012-02-22 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
WO2006127910A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
SI2371855T1 (sl) * 2005-08-05 2015-11-30 Araim Pharmaceuticals, Inc. Peptidi, ki ščitijo tkiva, in načini njihove uporabe
WO2007071248A2 (en) 2005-12-20 2007-06-28 Copenhagen University Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
EP2120869A2 (en) 2006-12-18 2009-11-25 Altus Pharmaceuticals Inc. Human growth hormone formulations
NZ621196A (en) 2008-01-22 2015-08-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Also Published As

Publication number Publication date
HK1215713A1 (en) 2016-09-09
KR101572286B1 (ko) 2015-11-27
NZ601868A (en) 2014-05-30
HK1143822A1 (en) 2011-01-14
MX2010008050A (es) 2011-02-23
EP2245056A2 (en) 2010-11-03
KR20200075044A (ko) 2020-06-25
IL207155A (en) 2015-07-30
JP2019123715A (ja) 2019-07-25
US20200360476A1 (en) 2020-11-19
US9580465B2 (en) 2017-02-28
KR20190085187A (ko) 2019-07-17
SG10202011946PA (en) 2020-12-30
JP2017002040A (ja) 2017-01-05
US20110263504A1 (en) 2011-10-27
KR20180041269A (ko) 2018-04-23
EP2933264A2 (en) 2015-10-21
KR20100117616A (ko) 2010-11-03
CN111346213A (zh) 2020-06-30
CN102066413A (zh) 2011-05-18
ES2539124T3 (es) 2015-06-26
KR20150134442A (ko) 2015-12-01
JP2014169308A (ja) 2014-09-18
EP2245056B1 (en) 2015-03-11
US8853358B2 (en) 2014-10-07
KR20180123731A (ko) 2018-11-19
MX356129B (es) 2018-05-16
SG10201604530SA (en) 2016-07-28
US20150239932A1 (en) 2015-08-27
AU2009206748B2 (en) 2014-03-20
EP2933264A3 (en) 2015-12-09
PL2245056T4 (pl) 2016-01-29
CA2712757A1 (en) 2009-07-30
CN102066413B (zh) 2015-01-21
PL2245056T3 (pl) 2015-08-31
CN104689298A (zh) 2015-06-10
KR20170049616A (ko) 2017-05-10
CN108743916A (zh) 2018-11-06
WO2009094172A3 (en) 2009-12-10
SG188161A1 (en) 2013-03-28
AU2009206748A1 (en) 2009-07-30
US20170232066A1 (en) 2017-08-17
JP2011527560A (ja) 2011-11-04
JP5542064B2 (ja) 2014-07-09
WO2009094172A2 (en) 2009-07-30
KR101768792B1 (ko) 2017-08-16
JP6309815B2 (ja) 2018-04-11
MX2019011592A (es) 2019-11-21
KR101850908B1 (ko) 2018-04-20
NZ587105A (en) 2012-09-28
JP2021073281A (ja) 2021-05-13
IL207155A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2012142320A8 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
NZ595063A (en) Polypeptides from neisseria meningitidis
SA521430398B1 (ar) Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد
EP2476697A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
NZ604818A (en) Variants of activin iib receptor polypeptides and uses thereof
EP2594582A3 (en) Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens
NZ599161A (en) Method for activation of helper t cell and composition for use in the method
UA100222C2 (uk) Тканинозахисні пептиди і їх застосування
TW200744642A (en) Novel peptides for use in the treatment of obesity
UA97953C2 (uk) Стабілізовані поліпептиди інсуліноподібного фактора росту
MX2008009493A (es) Peptido novedoso y uso del mismo.
MX344559B (es) Compuestos de hormona de crecimiento humana recombinante unidos al peg.
EP2455459A3 (en) Lipase variants for pharmaceutical use
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
WO2008087186A3 (en) Peptides for use in the treatment of obesity
JP2006506942A5 (enExample)
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
EP1960426A4 (en) NEW NEUROTROPHIC FACTOR AND USES THEREOF

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2017 BY HENRY HUGHES IP LIMITED

Effective date: 20160118

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 JAN 2016 BY HENRY HUGHES IP LIMITED

Effective date: 20160118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2018 BY CPA GLOBAL

Effective date: 20161210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2019 BY CPA GLOBAL

Effective date: 20171208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2020 BY CPA GLOBAL

Effective date: 20181206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2021 BY CPA GLOBAL

Effective date: 20191205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JAN 2022 BY CPA GLOBAL

Effective date: 20201211

LAPS Patent lapsed